Oppenheimer & CO Inc Catalyst Pharmaceuticals, Inc. Transaction History
Oppenheimer & CO Inc
- $6.52 Billion
- Q4 2024
A detailed history of Oppenheimer & CO Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 104,487 shares of CPRX stock, worth $2.26 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
104,487
Previous 81,409
28.35%
Holding current value
$2.26 Million
Previous $1.62 Million
34.73%
% of portfolio
0.03%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
345Shares Held
98.4MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$404 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$182 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$125 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$67.7 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$65.1 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.22B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...